Patents Assigned to SAGE THERAPEUTICS, INC.
-
Patent number: 12268697Abstract: Compounds are provided according to Formula (I): Formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3, R6, R7, R8, and n are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.Type: GrantFiled: March 13, 2024Date of Patent: April 8, 2025Assignee: Sage Therapeutics, Inc.Inventors: Francesco G. Salituro, Albert Jean Robichaud, Gabriel Martinez Botella
-
Patent number: 12264177Abstract: Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R19, R5, R3a, R1a, R1b, R2a, R2b, R4a, R4b, R6a, R6b, R7a, R7b, R11a, R11b, R12a, R12b, R18, RD, and q are defined herein. L is selected from the group consisting of: wherein A indicates the point of attachment at C17 and wherein X is selected from the group consisting of —C(O)N(R55a)(R55b), —N(R55a)(R55b), —N(R55b)C(O)(R55a), and R55C wherein R55c is carbon-bound substituted or unsubstituted heteroaryl or substituted or unsubstituted aryl. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) and methods of using the compounds, e.g., in the treatment of CNS-related disorders.Type: GrantFiled: March 26, 2024Date of Patent: April 1, 2025Assignee: Sage Therapeutics, Inc.Inventors: Maria Jesus Blanco-Pillado, Francesco G. Salituro, Marshall Lee Morningstar
-
Patent number: 12252509Abstract: Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R19, R5, R3a, R1a, R1b, R2a, R2b, R4a, R4b, R6a, R6b, R7a, R7b, R11a, R11b, R12a, R12b, R18, RD, and q are defined herein. L is selected from the group consisting of: wherein A indicates the point of attachment at C17 and wherein X is selected from the group consisting of —C(O)N(R55a)(R55b), —N(R55a)(R55b), —N(R55b)C(O)(R55a), and R55C wherein R55c is carbon-bound substituted or unsubstituted heteroaryl or substituted or unsubstituted aryl. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) and methods of using the compounds, e.g., in the treatment of CNS-related disorders.Type: GrantFiled: March 26, 2024Date of Patent: March 18, 2025Assignee: Sage Therapeutics, Inc.Inventors: Maria Jesus Blanco-Pillado, Francesco G. Salituro, Marshall Lee Morningstar
-
Patent number: 12201640Abstract: Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I): and pharmaceutically acceptable salts thereof; wherein , R1, R2, R3a, R3b, R4a, R4b, R5, R6, and R7 are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.Type: GrantFiled: December 23, 2021Date of Patent: January 21, 2025Assignee: Sage Therapeutics, Inc.Inventors: Gabriel Martinez Botella, Boyd L. Harrison, Albert Jean Robichaud, Francesco G. Salituro, Richard Thomas Beresis
-
Patent number: 12180247Abstract: Compounds are provided according to Formula (A): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3, R4, R5, R6, and RG are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.Type: GrantFiled: February 6, 2023Date of Patent: December 31, 2024Assignee: Sage Therapeutics, Inc.Inventors: Francesco G. Salituro, Albert Jean Robichaud, Gabriel Martinez Botella, Boyd L. Harrison, Andrew Griffin
-
Patent number: 12180248Abstract: Described herein are neuroactive steroids of the Formula (I): or a pharmaceutically acceptable salt thereof; wherein, R1, R2a, R2b, R3 and A are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and/or anesthesia.Type: GrantFiled: February 16, 2023Date of Patent: December 31, 2024Assignee: Sage Therapeutics, Inc.Inventors: Gabriel Martinez Botella, Francesco G. Salituro, Albert Jean Robichaud, Boyd L. Harrison
-
Patent number: 12129276Abstract: Compounds are provided according to Formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein X, Y, R1, R2a, R2b, R4a, R4b, R5a, R5b, R6a, R6b, R7, and R8 are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.Type: GrantFiled: March 2, 2023Date of Patent: October 29, 2024Assignee: SAGE THERAPEUTICS, INC.Inventors: Boyd L. Harrison, Gabriel Martinez Botella, Albert Jean Robichaud, Francesco G. Salituro
-
Patent number: 12129275Abstract: Compounds are provided according to Formula (I) and pharmaceutically acceptable salts thereof, wherein Z is a group of the formula (i), (ii), (iii), (iv), or (v), and wherein L1, L2, L3, X1, X2, Y, Rz4, Rz5, Rz6, n, R1, R2, R3a, R3b, R4a, R4b, R6a, R6b, R7a, R7b, R11a, R11b, R14, R17, R19, R20, R23a, R23b, and R24 are as defined herein, and pharmaceutical compositions thereof. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of CNS-related conditions in mammals.Type: GrantFiled: March 29, 2022Date of Patent: October 29, 2024Assignee: SAGE THERAPEUTICS, INC.Inventors: Ravindra B. Upasani, Boyd L. Harrison, Benny C. Askew, Jean-Cosme Dodart, Francesco G. Salituro, Albert Jean Robichaud
-
Patent number: 12122803Abstract: This invention relates to crystalline forms of anhydrous Compound (1) and pharmaceutical compositions thereof. Also disclosed herein are methods of making crystalline solid forms of Compound (1), and methods of using the crystalline forms of Compound (1) and pharmaceutical compositions thereof for modulating GABA activity (e.g., positive allosteric modulation of GABA activity) and treating CNS-related disorders.Type: GrantFiled: March 7, 2024Date of Patent: October 22, 2024Assignee: Sage Therapeutics, Inc.Inventors: Shanming Kuang, Tianrui Li
-
Patent number: 12083131Abstract: Described herein are methods of treating tremor, e.g., essential tremor, depression, e.g., postpostum depression; and anxiety disorder, the method comprising administering to a human subject suffering from tremor, e.g., essential tremor; depression, e.g., postpostum depression, an anxiety disorder with a neuroactive steroid or a composition comprising a neuroactive steroid (e.g., pregnanolone, allopregnanolone, alphadalone, ganaxolone, or alphaxolone).Type: GrantFiled: February 10, 2020Date of Patent: September 10, 2024Assignee: Sage Therapeutics, Inc.Inventors: Stephen Jay Kanes, Helen Colquhoun
-
Patent number: 12071453Abstract: Described herein are neuroactive steroids of the Formula (I): or a pharmaceutically acceptable salt thereof; wherein -------, R1, R2, R3, A and L are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and/or anesthesia.Type: GrantFiled: September 26, 2022Date of Patent: August 27, 2024Assignee: Sage Therapeutics, Inc.Inventors: Gabriel Martinez Botella, Boyd L. Harrison, Albert Jean Robichaud, Francesco G. Salituro, Robert Jason Herr, Robert Borbo Kargbo
-
Patent number: 12065463Abstract: Described herein are neuroactive steroids of the Formula (I): or a pharmaceutically acceptable salt thereof, wherein , A, R1, R2, R3a, R4a, R4b, R5, R7a, and R7b are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and/or anesthesia.Type: GrantFiled: October 24, 2022Date of Patent: August 20, 2024Assignee: Sage Therapeutics, Inc.Inventors: Gabriel Martinez Botella, Francesco G. Salituro, Albert Jean Robichaud, Boyd L. Harrison
-
Patent number: 12060386Abstract: Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R3a, R5, R6a, R6b, R17, R21a, R21b, Rm, Rn, R16a, R16b, R7a, R7b, R12a, R12b, R11a, R11b, R2a, R2b, R19, R4a, and R4b are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) and methods of using the compounds, e.g., in the treatment of CNS-related disorders.Type: GrantFiled: April 24, 2023Date of Patent: August 13, 2024Assignee: Sage Therapeutics, Inc.Inventors: Francesco G. Salituro, Albert Jean Robichaud
-
Patent number: 12048706Abstract: Described herein are methods of treating epilepsy or status epilepticus, e.g., convulsive status epilepticus, e.g., early status epilepticus, established status epilepticus, refractory status epilepticus, super-refractory status epilepticus, e.g., super-refractory generalized status epilepticus; non-convulsive status epilepticus, e.g., generalized status epilepticus, complex partial status epilepticus; generalized periodic epileptiform discharges; periodic lateralized epileptiform discharges; a seizure, e.g., acute repetitive seizures, cluster seizures, the method comprising administering to the subject a neuroactive steroid.Type: GrantFiled: February 3, 2022Date of Patent: July 30, 2024Assignee: Sage Therapeutics, Inc.Inventors: Kiran Reddy, Stephen J. Kanes
-
Patent number: 11999765Abstract: Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R19, R5, R3a, R1a, R1b, R2a, R2b, R4a, R4b, R6a, R6b, R7a, R7b, R11a, R11b, R12a, R12b, R18, RD, and q are defined herein. L is selected from the group consisting of: wherein A indicates the point of attachment at C17 and wherein X is selected from the group consisting of —C(O)N(R55a)(R55b), —N(R55a)(R55b), —N(R55b)C(O)(R55a), and R55C wherein R55c is carbon-bound substituted or unsubstituted heteroaryl or substituted or unsubstituted aryl. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) and methods of using the compounds, e.g., in the treatment of CNS-related disorders.Type: GrantFiled: June 13, 2023Date of Patent: June 4, 2024Assignee: Sage Therapeutics, Inc.Inventors: Maria Jesus Blanco-Pillado, Francesco G. Salituro, Marshall Lee Morningstar
-
Patent number: 11993628Abstract: Described herein are neuroactive steroids of Formula (I), Formula (V), or Formula (IX) or a pharmaceutically acceptable salt thereof; wherein each instance of R2, R3, R4, R5, R6, R7, R11a, R11b, R12, R16, R17, R19, and are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. Also provided are pharmaceutical compositions comprising a compound described herein and methods of use and treatment, e.g., such as for inducing sedation and/or anesthesia.Type: GrantFiled: April 28, 2021Date of Patent: May 28, 2024Assignee: Sage Therapeutics, Inc.Inventors: Albert Jean Robichaud, Gabriel Martinez Botella, Boyd L. Harrison, Francesco G. Salituro, Andrew Griffin, Maria Jesus Blanco-Pillado
-
Patent number: 11970514Abstract: Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R19, R5, R3a, R1a, R1b, R2a, R2b, R4a, R4b, R6a, R6b, R7a, R7b, R11a, R11b, R12a, R12b, R18, RD, and q are defined herein. L is selected from the group consisting of: wherein A indicates the point of attachment at C17 and wherein X is selected from the group consisting of —C(0)N(R55a)(R55b), —N(R55a)(R55b), —N(R55b)C(O)(R55a), and R55C wherein R55c is carbon-bound substituted or unsubstituted heteroaryl or substituted or unsubstituted aryl. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) and methods of using the compounds, e.g., in the treatment of CNS-related disorders.Type: GrantFiled: June 13, 2023Date of Patent: April 30, 2024Assignee: Sage Therapeutics, Inc.Inventors: Maria Jesus Blanco-Pillado, Francesco G. Salituro, Marshall Lee Morningstar
-
Patent number: 11952397Abstract: This invention relates to crystalline forms of anhydrous Compound (1) and pharmaceutical compositions thereof. Also disclosed herein are methods of making crystalline solid forms of Compound (1), and methods of using the crystalline forms of Compound (1) and pharmaceutical compositions thereof for modulating GABA activity (e.g., positive allosteric modulation of GABA activity) and treating CNS-related disorders.Type: GrantFiled: August 2, 2023Date of Patent: April 9, 2024Assignee: Sage Therapeutics, Inc.Inventors: Shanming Kuang, Tianrui Li
-
Patent number: 11945836Abstract: Described herein are neuroactive steroids of the Formula (II): or a pharmaceutically acceptable salt thereof; wherein A, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5, R6 and are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and/or anesthesia.Type: GrantFiled: October 4, 2022Date of Patent: April 2, 2024Assignee: Sage Therapeutics, Inc.Inventors: Gabriel Martinez Botella, Boyd L. Harrison, Albert Jean Robichaud, Francesco G. Salituro, Richard Thomas Beresis
-
Patent number: 11926646Abstract: Compounds are provided according to Formula (A): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1A, R1B, n, R2A, R2B, R3, and R4 are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.Type: GrantFiled: September 15, 2021Date of Patent: March 12, 2024Assignee: Sage Therapeutics, Inc.Inventors: Francesco G. Salituro, Albert Jean Robichaud, Gabriel Martinez Botella, Andrew Griffin, Boyd L. Harrison, Daniel La